Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new study just published in the Journal of General Internal Medicine makes a strong case for the importance of individualized application of specific treatments to older men diagnosed with prostate cancer — something which you would think ought to be evident to the majority of clinicians, but apparently wasn’t
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Co-morbidity, Diagnosis, Management, mortality, prognosis, risk | Leave a Comment »
Our friends at The Daily Mail in the UK have been spreading a story that men who eat 2.5 eggs or more a week have an 81 per cent increase in their risk for lethal prostate cancer compared to men who do not.
Filed under: Diagnosis, Prevention, Risk | Tagged: Daily Mail, eggs, Harvard | 25 Comments »
According to a report in today’s Daily Telegraph, the UK’s National Institute for Health and Clinical Excellence (NICE) has determined that “cabazitaxel would not be a cost effective use of limited NHS resources” for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Management, Treatment | Tagged: abiraterone, cabazitaxel, cost, NICE, UK | 2 Comments »
A new study in the Journal of Urology reports data on a cohort of 125 patients enrolled in the Physicians’ Health Study (PHS) who elected to be managed with watchful waiting for a minimum of 1 year after their initial diagnosis and who were followed for an average (mean) of 7.3 years.
Filed under: Management, Treatment | Tagged: active surveillance, long-term, outcome, quality of life, watchful waiting | 8 Comments »
Saw palmetto extract (made from the berries of the saw palmetto plant, Serenoa repens) is widely used by many men to prevent or treat benign enlargement of the prostate (benign prostatic hyperplasia). While it is not known to have any effect on prostate cancer, the use of saw palmetto has long been a topic of [...]
Filed under: Living with Prostate Cancer, Prevention | Tagged: benign prostatic hyperplasia, BPH, extract, saw palmetto | 3 Comments »
A report to be presented at the upcoming meeting of the American Society for Radiation Oncology (ASTRO) offers 5-year outcome data from a trial comparing conventional intensity-modulated radiation therapy (IMRT) to the more recently developed hypofractionated IMRT for men with localized prostate cancer.
Filed under: Management, Treatment, Uncategorized | Tagged: comparison, conventional, hypofractionated, IMRT, intensity-modulated radiation therapy, outcome | 1 Comment »
A new paper in the Proceedings of the National Academy of Sciences suggests the existence of a subset of “hypermutated” cell lines in some forms of aggressive prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: aggressive, genetics, hypermutation, mutation, variants | Leave a Comment »
Between 1981 and 1983 researchers collected and stored blood samples from 4,500 men in Copenhagen, Denmark, as part of the Copenhagen City Heart Study. These blood samples had been carefully stored — and otherwise unused — for nearly 30 years. In 2010, a new research team decided to measure the PSA levels in these blood [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, long-term, mortality, PSA, risk, screening | 5 Comments »
According to a company media release, the full results of the ALSYMPCA trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: Alpharadin, outcome, radium, radium-223, survival | Leave a Comment »
A new “mini-review” in BJU International provides a summary overiew of the “economic burden” of prostate cancer, largely based on data from the “western” nations (inclusive of Europe, North America, and Australasia).
Filed under: Living with Prostate Cancer | Tagged: burden, cost, economic | Leave a Comment »
According to a media release issued on Thursday by IRIS International, the U.S. Food & Drug Administration (FDA) has approved the company’s NADiA® ProsVue™ test as a prognostic marker that can “aid in identifying” men at reduced risk for recurrence of prostate cancer in the first 8 years after a prostatectomy.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: NADiA, prognosis, progression, ProsVue, radical prostatectomy | Leave a Comment »
According to a new study among Medicare beneficiaries in the USA, researchers have found that 6.9 percent of men having a prostate biopsy are hospitalized within 30 days of the biopsy compared to 2.7 percent of a control group of men who did not have a prostate biopsy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, complications, hospitalization, risk | 1 Comment »
A newly published report in the Journal of the American Medical Association provides data (from two large cohorts of patients) on the quality of sexual function among men undergoing first-line treatment for localized prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: brachytherapy, external beam radiation therapy, post-treatment, prediction, radical prostatectomy, sexual function | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site